| Literature DB >> 32290421 |
Sung-Woo Choi1, Hyeung-Kyu Cho1, Suyeon Park2, Jae Hwa Yoo3, Jae Chul Lee1, Min Jung Baek4, Hae-Dong Jang5, Joong Suk Cha1, Byung-Joon Shin1.
Abstract
A multimodal analgesic method was known to avoid the high-dose requirements and dose-dependent adverse events of opioids, and to achieve synergistic effects. The purpose of this study was to compare the efficacy of our multimodal analgesia (MMA) regimen with that of the patient-controlled analgesia (PCA) method for acute postoperative pain management. Patients who underwent one or two-level posterior lumbar fusion (PLF) followed by either MMA or PCA administration at our hospital were compared for pain score, additional opioid and non-opioid consumption, side effects, length of hospital stay, cost of pain control, and patient satisfaction. From 2016 through 2017, a total 146 of patients were screened. After propensity score matching, 66 remained in the PCA and 34 in the MMA group. Compared with the PCA group, the MMA group had a shorter length of hospital stay (median (interquartile range): 7 days (5-8) vs. 8 (7-11); P = 0.001) and lower cost of pain control (70.6 ± 0.9 USD vs. 173.4 ± 3.3, P < 0.001). Baseline data, clinical characteristics, pain score, additional non-opioid consumption, side effects, and patient subjective satisfaction score were similar between the two groups. The MMA seems to be a good alternative to the PCA after one or two-level PLF.Entities:
Keywords: analgesia; arthrodesis; cost; length of stay; lumbar vertebra; multimodal treatment; pain; patient-controlled; postoperative; preemptive
Year: 2020 PMID: 32290421 PMCID: PMC7230859 DOI: 10.3390/jcm9041087
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Patient controlled analgesia (PCA) vs. Multimodal analgesia (MMA) protocol.
| PCA | MMA | ||
|---|---|---|---|
| Preoperative | No intervention | Celecoxib 200 mg PO | |
| Acetaminophen 650 mg PO | |||
| Pregabalin 75 mg PO | |||
| Oxycodone 10 mg PO | |||
| Dexamethasone 10 mg IV | |||
| Ramosetron 0.3 mg IV | |||
| Intraoperative | Anesthesia * | Induction—Propofol | |
| Maintenance—Desflurane, Remifentanil | |||
| Recovery—Fentanyl | |||
| Surgery | No intervention | Bupivacaine + Epinephrine 10 mL SQ ** (prior to incision) | |
| Postoperative Day 0 | Recovery room | 1. PCA keep | 1. Tramadol 50 mg IV |
| Fentanyl 1.5 mg IV | |||
| Nefopam 100 mg IV | |||
| Propacetamol 5 g IV | |||
| Ramosetron 0.6 mg IV | |||
| Palonosetron 0.075 mg IV | |||
| 2. Fentanyl IV (PRN) | 2. Fentanyl (PRN) | ||
| In-patient room | 1. PCA keep | 1. MMA PO medication | |
| Celecoxib 100 mg PO, 1-tab q12h | |||
| Acetaminophen 650 mg PO, 1-tab q8h | |||
| Pregabalin 75 mg PO, 1-tab q12h | |||
| Oxycodone/Naloxone 10 mg PO, 1-tab q6h | |||
| 2. PRN *** | 2. PRN *** | ||
| 3. Ramosetron 0.9 mg IV | |||
| Postoperative Day 1,2 | 1. PCA keep | 1. MMA PO medication | |
| 2. Routine fluid **** | 2. Routine fluid **** | ||
| 3. PRN *** | 3. PRN *** | ||
PCA = patient-controlled analgesia; MMA = multimodal analgesia; PO = per os; IV = intravenous; SQ = subcutaneous; PRN = pro re nata * Anesthesia-(1) Induction: 1% propofol 1.5–3 mg/kg with 2% lidocaine 40 mg pretreatment, rocuronium 6 mg/kg; (2) Maintenance: inhaled anesthetics (desflurane) with Bispectral index (BIS) monitoring, remifentanil continuous infusion 0.1–1 ug/kg/min; (3) Recovery: Fentanyl 50–100 ug iv after turned off the remifentanil infusion. (with neuromuscular recovery using pyridostigmine and glycopyrrolate) ** 0.5% Bupivacaine 5 mL + normal saline 4 mL + epinephrine (0.1 mg/mL) 1 mL *** PRN—Tramadol 50 mg IV, Pethidine 50 mg IV **** Routine fluid—Acupan 60 mg IV, Marobiven 6.6 ml IV, Methocarbamol 3 g IV, Myraxan 30 mg IV, Traumeel 6.6 mg IV, Nasea 0.6 mg IV.
Baseline data and clinical characteristics.
| MMA (n = 34) | Before Matching | After Matching | ||||
|---|---|---|---|---|---|---|
| PCA (n = 100) | PCA (n = 66) | |||||
| Age (years) a | 62.8 ± 11.0 | 67.1 ± 11.8 | 0.043* | 64.5 ± 11.7 | 0.338 | |
| Sex b | Male | 17 (50.0%) | 41 (41.0%) | 0.360 | 29 (43.9%) | 0.565 |
| Female | 17 (50.0%) | 59 (59.0%) | 37 (56.1%) | |||
| Smoking b | 6 (17.6%) | 18 (18.0%) | 0.963 | 9 (13.6%) | 0.595 | |
| BMI (kg/m2) a | 24.6 ± 2.7 | 27.0 ± 3.9 | 0.001* | 25.4 ± 3.4 | 0.346 | |
| Pain position b | 0.803 | 0.784 | ||||
| Axial | 4 (11.8%) | 9 (9.0%) | 5 (7.6%) | |||
| Radiating to leg | 15 (44.1%) | 50 (50%) | 31 (47.0%) | |||
| Combined | 15 (44.1%) | 41 (41%) | 30 (45.5%) | |||
| Preoperative NRS a | 7.5 ± 1.1 | 7.4 ± 1.0 | 0.375 | 7.2 ± 1.0 | 0.075 | |
| Preoperative ODI a | 23.6 ± 4.9 | 24.1 ± 5.2 | 0.659 | 24.8 ± 4.2 | 0.762 | |
| Preoperative medication c | 1.000 | 0.999 | ||||
| None | 22 (64.7%) | 62 (62.0%) | 44 (66.7%) | |||
| AAP/NSAIDs | 2 (5.9%) | 7 (7.0%) | 3 (4.5%) | |||
| Weak opioids | 3 (8.8%) | 9 (9.0%) | 6 (9.1%) | |||
| Strong opioids | 1 (2.9%) | 4 (4%) | 3 (4.5%) | |||
| Combination | 6 (17.6%) | 18 (18.0%) | 10 (15.2%) | |||
| ASA class a | 1.8 ± 0.5 | 1.8 ± 0.6 | 0.966 | 1.8 ± 0.6 | 0.858 | |
| AIBG (No.) b | 5 (14.7%) | 22 (22.0%) | 0.360 | 14 (21.2%) | 0.432 | |
| Suction drain use (No.) b | 6 (17.6%) | 22 (22.0%) | 0.590 | 11 (16.7%) | 0.902 | |
| Intraoperative complication c | 3 (8.8%) | 6 (6.0%) | 0.692 | 3 (4.5%) | 0.406 | |
| Operation time (min) a | 220.8 ± 53.0 | 222.5 ± 51.7 | 0.878 | 220.4 ± 48.1 | 0.985 | |
MMA = multimodal analgesia; PCA = patient-controlled analgesia; BMI = body mass index; NRS = numeric rating scale (0–10); ODI = Oswestry Disability Index; ASA = American Society of Anesthesiologists; AIBG = autologous iliac bone graft; a Mann–Whitney U test; b Pearson chi-squared test; c Fisher’s exact test; * indicates statistical significance.
Figure 1Study design and flowchart.
Postoperative outcomes.
| MMA (n = 34) | PCA (n = 66) | |||
|---|---|---|---|---|
| Mean NRS | POD 0 | 5.7 ± 1.9 | 5.4 ± 1.8 | 0.302 |
| POD 1 | 4.2 ± 1.9 | 3.8 ± 1.5 | 0.282 | |
| POD 2 | 3.4 ± 1.8 | 3.2 ± 1.5 | 0.901 | |
| Additional opioids consumption (ME/day) | POD 0 | 2.7 ± 6.7 | 5.1 ± 8.3 | 0.137 |
| POD 1 | 2.2 ± 5.9 | 8.2 ± 16.1 | 0.059 | |
| POD 2 | 1.5 ± 4.8 | 7.7 ± 14.5 | 0.014* | |
| Additional non-opioids analgesia consumption (mg/day) | POD 0 | 54.4 ± 81.1 | 37.1 ± 59.7 | 0.423 |
| POD 1 | 25.6 ± 49.6 | 51.5 ± 79.9 | 0.159 | |
| POD 2 | 30.9 ± 65.2 | 34.8 ± 66.2 | 0.393 |
ME = morphine equivalents; POD = postoperative day; a Mann–Whitney U test; * indicates statistical significance P < 0.05.
Side effects.
| MMA (n = 34) | PCA (n = 66) | |||
|---|---|---|---|---|
| Nausea/Vomiting and Antiemetic drug use (%) a | POD 0 | 16 (47.1%) | 42 (63.6%) | 0.112 |
| POD 1 | 16 (47.1%) | 42 (63.6%) | 0.112 | |
| POD 2 | 9 (26.5%) | 29 (43.9%) | 0.088 | |
| Abdominal discomfort (%) b | POD 0 | 9 (26.5%) | 15 (22.7%) | 0.577 |
| POD 1 | 8 (23.5%) | 12 (18.2%) | 0.942 | |
| POD 2 | 1 (2.9%) | 6 (9.1%) | 0.417 |
POD = postoperative day; a Pearson chi-squared test; b Fisher’s exact test.
Length of hospital stay, cost for pain control, and subjective satisfaction outcome.
| MMA (n = 34) | PCA (n = 66) | ||
|---|---|---|---|
| Length of hospital stay a (day) | 7 (5–8) | 8 (7–11) | 0.001* |
| Total Cost (USD) b | 70.6 ± 0.9 | 173.4 ± 3.3 | <0.001* |
| Routine use | |||
| Pump setup | 80.9 ± 0.0 | ||
| Pump PCA per day | 15.1 ± 3.2 | ||
| Pump medication | 76.5 ± 0.0 | ||
| MMA medication | 66.9 ± 0.0 | ||
| Rescue medication | |||
| Tramadol b | 0.6 ± 0.8 | 0.7 ± 0.8 | 0.315 |
| Opioid (Demerol) b | 0.1 ± 0.2 | 0.2 ± 0.3 | 0.022 |
| Subjective satisfaction (1–5) b, c | 2.5 ± 0.8 | 2.2 ± 0.7 | 0.108 |
a Mann–Whitney U test and summary statistics are presented as median (IQR); b Student t-test; c 1: Very satisfied, 2: Somewhat satisfied, 3: Neutral, 4: Somewhat dissatisfied, 5: Very dissatisfied; * indicates statistical significance P < 0.05.